Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?
作者信息
Niegisch Günter
机构信息
Department of Urology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
出版信息
Transl Androl Urol. 2019 Jul;8(Suppl 3):S283-S286. doi: 10.21037/tau.2019.04.04.
Abstract
摘要
相似文献
1
Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?对于计划进行根治性膀胱切除术的低风险肌层浸润性膀胱癌患者，我们是否应省去新辅助化疗？
Transl Androl Urol. 2019 Jul;8(Suppl 3):S283-S286. doi: 10.21037/tau.2019.04.04.
2
A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.从诊断到新辅助化疗再到根治性膀胱切除术的时间对肌层浸润性膀胱癌患者生存影响的回顾性分析
J Urol. 2016 Apr;195(4 Pt 1):880-5. doi: 10.1016/j.juro.2015.11.024. Epub 2015 Nov 18.
3
4
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.新辅助化疗治疗肌层浸润性膀胱癌患者的血栓栓塞事件的发生率、特征及意义。
J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017. Epub 2016 Jun 14.
5
Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.根治性膀胱切除术联合或不联合新辅助化疗后的病理 T0：一个有用的替代指标。
J Urol. 2014 Apr;191(4):898-906. doi: 10.1016/j.juro.2013.10.142. Epub 2013 Dec 1.
6
The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study.新辅助化疗对根治性膀胱切除术治疗膀胱癌患者围手术期结局的影响：一项基于人群的研究。
Eur Urol. 2014 Sep;66(3):561-8. doi: 10.1016/j.eururo.2014.01.014. Epub 2014 Jan 24.
8
Neoadjuvant Platinum-Based Chemotherapy is an Independent Predictor for Preoperative Thromboembolic Events in Bladder Cancer Patients Undergoing Radical Cystectomy.新辅助铂类化疗是接受根治性膀胱切除术的膀胱癌患者术前血栓栓塞事件的独立预测因素。
Curr Urol. 2017 Aug;10(3):132-135. doi: 10.1159/000447166. Epub 2017 Jul 30.
9
Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study.新辅助化疗对肌层浸润性膀胱癌根治性膀胱切除术患者的影响：一项回顾性、多机构研究。
Jpn J Clin Oncol. 2020 Jan 24;50(1):73-79. doi: 10.1093/jjco/hyz137.
10
Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.随机 III 期研究：新辅助化疗（甲氨蝶呤、多柔比星、长春碱和顺铂）联合根治性膀胱切除术与单独根治性膀胱切除术治疗肌层浸润性膀胱癌的比较：日本临床肿瘤学组研究 JCOG0209。
Ann Oncol. 2014 Jun;25(6):1192-8. doi: 10.1093/annonc/mdu126. Epub 2014 Mar 24.
本文引用的文献
1
A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.肌层浸润性膀胱癌新辅助化疗的风险分层方法：对低危疾病患者的影响。
World J Urol. 2019 Aug;37(8):1605-1613. doi: 10.1007/s00345-018-2551-9. Epub 2018 Nov 3.
2
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.新辅助化疗方案在接受膀胱癌根治性切除术的肌层浸润性膀胱癌患者中的降期作用和生存结局。
JAMA Oncol. 2018 Nov 1;4(11):1535-1542. doi: 10.1001/jamaoncol.2018.3542.
3
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.
4
Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.新辅助化疗后膀胱切除术后残留癌患者的肿瘤学结局：病理分期匹配分析。
Eur Urol. 2017 Nov;72(5):660-664. doi: 10.1016/j.eururo.2017.05.016. Epub 2017 May 22.
5
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.肌层浸润性膀胱癌分子亚型对新辅助化疗后反应和生存预测的影响。
Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.
6
A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.辅助和新辅助化疗治疗上尿路尿路上皮癌的系统评价和荟萃分析。
Eur Urol. 2014 Sep;66(3):529-41. doi: 10.1016/j.eururo.2014.03.003. Epub 2014 Mar 16.
7
Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.根治性膀胱切除术联合或不联合新辅助化疗后的病理 T0：一个有用的替代指标。
J Urol. 2014 Apr;191(4):898-906. doi: 10.1016/j.juro.2013.10.142. Epub 2013 Dec 1.
8
Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.优化根治性膀胱切除术前新辅助化疗的患者选择。
J Urol. 2014 Jan;191(1):40-7. doi: 10.1016/j.juro.2013.07.061. Epub 2013 Jul 30.
9
Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?肌层浸润性膀胱癌患者的新辅助化疗：哪些患者受益？
Eur Urol. 2013 Sep;64(3):355-7. doi: 10.1016/j.eururo.2013.06.002. Epub 2013 Jun 12.
10
A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.经膀胱镜活检术前预测临床 T2 期膀胱癌病理升级和肿瘤学结局的决策模型。
BJU Int. 2013 Feb;111(2):240-8. doi: 10.1111/j.1464-410X.2012.11424.x. Epub 2012 Aug 29.
Zotero 插件